C4 Therapeutics, Inc (CCCC)

Etorro trading 970x250
C4 Therapeutics, Inc (CCCC) Logo

About C4 Therapeutics, Inc

C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Address: 490 Arsenal Way, Watertown, MA, United States, 02472

C4 Therapeutics, Inc News and around…

Latest news about C4 Therapeutics, Inc (CCCC) common stock and company :

Is C4 Therapeutics, Inc. (CCCC) A Good Stock To Buy?
12 Jan, 2022 Yahoo! Finance

In this article we will analyze whether C4 Therapeutics, Inc. (NASDAQ:CCCC) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead […]

C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio
10 Jan, 2022 Yahoo! Finance

– Initial Phase 1 Data for CFT7455, a Novel IKZF1/3 Degrader, Expected in 1H 2022– – IND Clearance Achieved for CFT8634, a Degrader Targeting BRD9; On Track to Initiate Phase 1 Trial in Synovial Sarcoma and SMARCB1-null Solid Tumors in 1H 2022– – CFT1946, a BRAF V600X Degrader, Advancing Towards the Clinic with IND Submission and Phase 1 Trial Initiation Planned for 2H 2022– – Strengthened Leadership Team with Addition of Scott Boyle, Ph.D., MBA as Chief Business Officer– –Year-End Cash, Cash Eq

C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
03 Jan, 2022 Yahoo! Finance

WATERTOWN, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 10:30 a.m. EST. A live webcast of the presentation can be accessed under “Events & Presentations” in the Inve

What Makes C4 Therapeutics, Inc. (CCCC) a New Buy Stock
29 Dec, 2021 Yahoo! Finance

C4 Therapeutics, Inc. (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

How The Parts Add Up: FPX Headed For $152
21 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust US Equity Opportunities ETF (FPX), we found that the implied analyst target price for the ETF based upon its underlying holdings is $152.29 per unit.

C4 Therapeutics Added to NASDAQ Biotechnology Index
17 Dec, 2021 Yahoo! Finance

WATERTOWN, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced its inclusion on the NASDAQ Biotechnology Index (Nasdaq: NBI), effective on December 20, 2021. The NASDAQ Biotechnology Index tracks the performance of a set of biotechnology and pharmaceutical companies, classified by the

C4 Therapeutics (CCCC) Sees Hammer Chart Pattern: Time to Buy?
01 Dec, 2021 Yahoo! Finance

C4 Therapeutics (CCCC) has been struggling lately, but the selling pressure may be coming to an end soon.

Benzinga's Top Ratings Upgrades, Downgrades For November 23, 2021
23 Nov, 2021 FinancialContent

Upgrades Keefe, Bruyette & Woods upgraded the previous rating for CBRE Group Inc (NYSE:CBRE) from Market Perform to ...

C4 Therapeutics, Inc. (CCCC) Moves to Buy: Rationale Behind the Upgrade
22 Nov, 2021 Yahoo! Finance

C4 Therapeutics, Inc. (CCCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Oversold Conditions For C4 Therapeutics (CCCC)
19 Nov, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results
10 Nov, 2021 Yahoo! Finance

– Phase 1/2 study of CFT7455, a Novel IKZF1/3 Degrader, Progressing with Data Expected in 2022; Trial-in-Progress Poster Accepted for Presentation at 63rd ASH Annual Meeting – – Investigational New Drug (IND) Application for CFT8634, a Degrader Targeting BRD9 for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors, On Track for Submission by YE 2021 – – Development Candidate CFT1946, a BRAF V600X Degrader, in IND-enabling Activities; C4T to Advance CFT1946 Independently – – On Track to Del

Why C4 Therapeutics (CCCC) Might Surprise This Earnings Season
10 Nov, 2021 Yahoo! Finance

C4 Therapeutics (CCCC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Analysts Forecast 11% Upside For FPX
04 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust US Equity Opportunities ETF (FPX), we found that the implied analyst target price for the ETF based upon its underlying holdings is $147.58 per unit.

Hedge Funds Are Piling Into C4 Therapeutics, Inc. (CCCC)
26 Oct, 2021 Yahoo! Finance

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June. At Insider Monkey, we follow nearly 900 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]

Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
14 Oct, 2021 FinancialContent

Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX:REI) was changed from Neutral to Buy. For the second ...

C4 Therapeutics (NASDAQ:CCCC) pulls back 8.2% this week, but still delivers shareholders notable 85% return over 1 year
09 Oct, 2021 Yahoo! Finance

These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But one can do...

Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
30 Sep, 2021 FinancialContent

Upgrades For Cabot Oil & Gas Corp (NYSE:COG), Wolfe Research upgraded the previous rating of Peer Perform to Outperform. For the ...

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
22 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Director Of C4 Therapeutics Sold $3.98 Million In Stock
17 Sep, 2021 Yahoo! Finance

Elena Prokupets, Director at C4 Therapeutics (NASDAQ:CCCC), made a large insider sell on September 16, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Prokupets sold 81,676 shares of C4 Therapeutics at a price of $49.48 per share. The total transaction amounted to $3,984,396. Prokupets still owns a total of 510,385 of C4 Therapeutics worth, $25,544,769. C4 Therapeutics shares are trading up 1.11% at $50.05 at

The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
14 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
10 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stock Upgrades: C4 Therapeutics Shows Rising Relative Strength
10 Sep, 2021 FinancialContent

C4 Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Analysts Forecast 11% Gains Ahead For FPX
26 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust US Equity Opportunities ETF (FPX), we found that the implied analyst target price for the ETF based upon its underlying holdings is $143.89 per unit.

C4 Therapeutics Shows Market Leadership With Jump To 83 RS Rating
19 Aug, 2021 FinancialContent

A Relative Strength Rating upgrade for C4 Therapeutics shows improving technical performance.

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

C4 Therapeutics Multiple Myeloma Candidate Scores FDA Orphan Drug Tag
12 Aug, 2021 FinancialContent

TheFDA has granted Orphan Drug DesignationtoC4 Therapeutics Inc(NASDAQ: CCCC) CFT7455 for multiple ...

C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
11 Aug, 2021 FinancialContent
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma
11 Aug, 2021 FinancialContent
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma
11 Aug, 2021 Yahoo! Finance

WATERTOWN, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to CFT7455 for the treatment of multiple myeloma. The FDA’s Office of Orphan Products Development grants orphan designation status t

Notable Two Hundred Day Moving Average Cross - CCCC
11 Aug, 2021 FinancialContent

In trading on Wednesday, shares of C4 Therapeutics Inc (CCCC) crossed below their 200 day moving average of $36.29, changing hands as low as $35.38 per share. C4 Therapeutics Inc shares are currently trading down about 3.1% on the day..

C4 Therapeutics, Inc (CCCC) is a NASDAQ Common Stock listed in ,

970x250